期刊
BIOMEDICINES
卷 9, 期 9, 页码 -出版社
MDPI
DOI: 10.3390/biomedicines9091098
关键词
colitis; Lactococcus; microbiome
资金
- NIH [R43DK117726, R44DK117726]
Inflammatory bowel disease (IBD) is a gastrointestinal inflammation disease comprising Crohn's disease and ulcerative colitis, with multifactorial etiology and treatments focusing on reducing inflammatory signals. Studies have shown that a surface layer protein A (SlpA) of certain probiotics possesses anti-inflammatory properties to alleviate colitis in mice.
Inflammatory bowel disease (IBD) is characterized by gastrointestinal inflammation comprised of Crohn's disease and ulcerative colitis. Centers for Disease Control and Prevention report that 1.3% of the population of the United States (approximately 3 million people) were affected by the disease in 2015, and the number keeps increasing over time. IBD has a multifactorial etiology, from genetic to environmental factors. Most of the IBD treatments revolve around disease management, by reducing the inflammatory signals. We previously identified the surface layer protein A (SlpA) of Lactobacillus acidophilus that possesses anti-inflammatory properties to mitigate murine colitis. Herein, we expressed SlpA in a clinically relevant, food-grade Lactococcus lactis to further investigate and characterize the protective mechanisms of the actions of SlpA. Oral administration of SlpA-expressing L. lactis (R110) mitigated the symptoms of murine colitis. Oral delivery of R110 resulted in a higher expression of IL-27 by myeloid cells, with a synchronous increase in IL-10 and cMAF in T cells. Consistent with murine studies, human dendritic cells exposed to R110 showed exquisite differential gene regulation, including IL-27 transcription, suggesting a shared mechanism between the two species, hence positioning R110 as potentially effective at treating colitis in humans.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据